Novo Nordisk A/S buy piccolo90
Summary
This prediction ended on 20.02.19 with a price of €43.83. With a performance of 3.75%, the BUY prediction by piccolo90 for Novo Nordisk A/S closed with a slight gain. piccolo90 has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by piccolo90 for this prediction
In the thread Novo Nordisk A/S diskutieren
piccolo90 stimmt dem Crowdsentiment von 'Buy' zu
piccolo90 stimmt am 20.08.2018 dem Buy-Crowdsentiment mit dem Kursziel 57.9€ zu.
Stopped prediction by piccolo90 for Novo Nordisk A/S
Novo Nordisk A/S
29.06.16
12.08.16
12.08.16